Arcutis Biotherapeutics (NASDAQ:ARQT) Downgraded by Mizuho
Mizuho cut shares of Arcutis Biotherapeutics (NASDAQ:ARQT – Free Report) from a buy rating to a neutral rating in a research report released on Thursday morning, MarketBeat.com reports. ARQT has been the subject of a number of other reports. TD Cowen lowered their price target on Arcutis Biotherapeutics from $65.00 to $50.00 and set an […]
More Stories
Shoppers Empty Grocery Store Shelves Ahead of Massive Winter Storm
By Jacki Thrapp NASHVILLE, Tenn.—Shoppers across America are clearing grocery store shelves ahead of this weekend’s winter blast. Entire sections...
TikTok US Deal Finalized: What to Know
By Catherine Yang Four months after President Donald Trump issued an executive order for the United States to acquire TikTok...
Trump Says ‘Big Force’ of US Naval Ships Headed Toward Iran
By Jacob Burg President Donald Trump said on Jan. 22 that the U.S. Navy has sent a large flotilla toward...
US Airlines Issue Travel Waivers as Winter Storm Threatens Widespread Disruption
By Evgenia Filimianova U.S. airlines have rolled out sweeping travel waivers as a powerful winter storm threatens to disrupt air...
Silver Hits Record $100 Amid Red‑Hot Metals Market
By Andrew Moran Silver prices continued their meteoric ascent at the end of the holiday-shortened trading week as the white...
US to Gain “Total Access” to Greenland Without Payment, Trump Says
By Tom Ozimek President Donald Trump said on Jan. 22 that the United States is negotiating an arrangement to secure...